214390.KS KSC
Kyongbo Pharmaceutical Co., Ltd
1W: +0.6%
1M: -1.8%
3M: +1.5%
YTD: -8.8%
1Y: +8.0%
3Y: -19.1%
5Y: -58.1%
₩5,420.00 ($4.03)
-20.00 (-0.37%)
Weekly Expected Move ±2.9%
₩5103
₩5261
₩5420
₩5579
₩5737
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$319.2B
+12.5% ▲
5Y CAGR: +4.7%
Total Liabilities
$173.8B
+26.2% ▲
5Y CAGR: +12.3%
Shareholders Equity
$145.4B
-0.5% ▼
5Y CAGR: -1.4%
Cash & Investments
$8.0B
+31.3% ▲
5Y CAGR: -17.4%
Total Debt
$126.7B
+38.5% ▲
5Y CAGR: +14.9%
Net Debt
$119.4B
+36.8% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $4.3B | $6.3B | $4.5B | $4.1B | $7.2B |
| Short-Term Investments | $0 | $870M | $870M | $2.0B | $820M |
| Cash & ST Investments | $4.3B | $7.2B | $5.3B | $6.1B | $8.0B |
| Net Receivables | $46.9B | $50.8B | $56.2B | $52.3B | $66.6B |
| Inventory | $57.7B | $57.4B | $70.7B | $90.6B | $0 |
| Other Current Assets | $1.4B | $1.3B | $2.1B | $171M | $82.3B |
| Total Current Assets | $111.2B | $116.3B | $135.9B | $151.9B | $159.1B |
| Property, Plant & Equip. | $95.7B | $93.9B | $96.1B | $99.9B | $128.0B |
| Goodwill & Intangibles | $3.4B | $3.2B | $3.6B | $4.0B | $3.9B |
| Long-Term Investments | $16.6B | $11.9B | $13.7B | $9.9B | $10.2B |
| Other Non-Current Assets | $310 | $3.2B | $17.0B | $4.6B | $4.7B |
| Total Non-Current Assets | $125.8B | $124.2B | $130.4B | $131.9B | $160.4B |
| Total Assets | $237.0B | $240.5B | $266.3B | $283.9B | $319.2B |
| — Liabilities — | |||||
| Accounts Payable | $16.4B | $14.7B | $22.8B | $15.0B | $14.8B |
| Short-Term Debt | $55.3B | $64.0B | $73.2B | $89.3B | $102.3B |
| Deferred Revenue | $15.0B | $180M | $0 | $0 | $310M |
| Other Current Liabilities | $13.7B | $13.7B | $17.8B | $8.2B | $26.0B |
| Total Current Liabilities | $88.8B | $95.6B | $118.3B | $132.7B | $147.2B |
| Long-Term Debt | $225M | $135M | $45M | $0 | $24.0B |
| Other Non-Current Liab. | $2.0B | $1.0B | $2.0B | $4.0B | $2.2B |
| Total Non-Current Liabilities | $2.5B | $1.3B | $3.7B | $5.1B | $26.6B |
| Total Liabilities | $91.3B | $96.8B | $121.9B | $137.7B | $173.8B |
| — Equity — | |||||
| Common Stock | $12.0B | $12.0B | $12.0B | $12.0B | $12.0B |
| Retained Earnings | $94.6B | $94.7B | $96.0B | $98.3B | $93.2B |
| Accumulated OCI | $4.0B | $2.0B | $0 | $0 | $535M |
| Total Stockholders Equity | $145.7B | $143.7B | $144.4B | $146.2B | $145.4B |
| Total Liabilities & Equity | $237.0B | $240.5B | $266.3B | $283.9B | $319.2B |
| — Key Metrics — | |||||
| Total Debt | $56.6B | $64.5B | $75.9B | $91.4B | $126.7B |
| Net Debt | $52.3B | $58.2B | $71.5B | $87.3B | $119.4B |
| Total Investments | $16.6B | $12.8B | $14.5B | $11.9B | $11.0B |